Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Sell
34
GNMSF Quote, Financials, Valuation and Earnings
Last price:
$222.00
Seasonality move
:
7.37%
Day range:
$219.00 - $223.50
52-week range:
$192.20 - $323.02
Dividend yield:
0%
P/E ratio:
21.10x
P/S ratio:
5.01x
P/B ratio:
2.95x
Volume:
3.7K
Avg. volume:
2.7K
1-year change:
-30.58%
Market cap:
$14.1B
Revenue:
$2.4B
EPS (TTM):
$10.52
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Genmab AS has -- downside to fair value with a price target of -- per share.
GNMSF vs. S&P 500
-
Over the past 5 trading days, Genmab AS has overperformed the S&P 500 by 7.96% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Genmab AS does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Genmab AS has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Genmab AS reported revenues of $816.4M.
Earnings Growth
-
Genmab AS earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Genmab AS reported earnings per share of $2.92.
Enterprise value:
11.5B
EV / Invested capital:
--
Price / LTM sales:
5.01x
EV / EBIT:
12.00x
EV / Revenue:
3.99x
PEG ratio (5yr expected):
1.41x
EV / Free cash flow:
12.00x
Price / Operating cash flow:
15.08x
Enterprise value / EBITDA:
11.70x
Gross Profit (TTM):
$2.8B
Return On Assets:
12.66%
Net Income Margin (TTM):
23.71%
Return On Equity:
14.86%
Return On Invested Capital:
14.86%
Operating Margin:
38.25%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.7B | $2.4B | $2.9B | $688.1M | $816.4M | |
| Gross Profit | -- | $2.4B | $2.8B | $676.6M | $776.2M | |
| Operating Income | $631.9M | $874.7M | $943.8M | $246.1M | $312.3M | |
| EBITDA | $1B | $773.4M | $983.7M | $403.6M | $272.5M | |
| Diluted EPS | $12.02 | $9.16 | $10.52 | $4.66 | $2.92 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.1B | $3.4B | $3.8B | $4.7B | $3.5B | |
| Total Assets | $3.4B | $3.7B | $4.1B | $5B | $5.9B | |
| Current Liabilities | $356M | $285.5M | $394.9M | $411M | $686.8M | |
| Total Liabilities | $480.1M | $421.2M | $532.5M | $584.4M | $1.2B | |
| Total Equity | $2.9B | $3.3B | $3.5B | $4.4B | $4.8B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $515.2M | $912.4M | $983.5M | $297M | $308.8M | |
| Cash From Investing | -$404.5M | -$158.7M | -$1.5B | $147.4M | $2.1M | |
| Cash From Financing | -$122.3M | -$72.6M | -$580.7M | $3M | -$51.7M | |
| Free Cash Flow | $476.3M | $850.4M | $958.8M | $282.7M | $301.5M | |
GNMSF
Sector
Market Cap
$14.1B
$47.5M
Price % of 52-Week High
68.73%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
3.83%
-0.74%
1-Year Price Total Return
-30.58%
-34.04%
Beta (5-Year)
1.042
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$215.40
200-day SMA
Sell
Level
$254.43
Bollinger Bands (100)
Sell
Level
209.19 - 256.43
Chaikin Money Flow
Sell
Level
-280.6K
20-day SMA
Buy
Level
$210.72
Relative Strength Index (RSI14)
Buy
Level
56.80
ADX Line
Buy
Level
23.64
Williams %R
Sell
Level
-10.5263
50-day SMA
Buy
Level
$214.42
MACD (12, 26)
Buy
Level
1.52
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
105.9K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (25.4267)
Buy
CA Score
(Annual)
Level (2.343)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-6.7058)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.
Stock Forecast FAQ
In the current month, GNMSF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GNMSF average analyst price target in the past 3 months is --.
-
Where Will Genmab AS Stock Be In 1 Year?
According to analysts, the consensus estimate is that Genmab AS share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Genmab AS?
Analysts are divided on their view about Genmab AS share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Genmab AS is a Sell and believe this share price will rise from its current level to --.
-
What Is Genmab AS's Price Target?
The price target for Genmab AS over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GNMSF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Genmab AS is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of GNMSF?
You can purchase shares of Genmab AS via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Genmab AS shares.
-
What Is The Genmab AS Share Price Today?
Genmab AS was last trading at $222.00 per share. This represents the most recent stock quote for Genmab AS. Yesterday, Genmab AS closed at $222.00 per share.
-
How To Buy Genmab AS Stock Online?
In order to purchase Genmab AS stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Why Is Marvell Stock Up?
Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
